Cargando…

Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats

Parkinson's disease (PD) is the second most common neurodegenerative disorder, and the main cause of PD is still not known. Until now, no cure for Parkinson's disease is yet in sight. Caffeic acid phenethyl ester (CAPE) is a polyphenolic component of the propolis, which can be derived from...

Descripción completa

Detalles Bibliográficos
Autores principales: Soner, Burak Cem, Acikgoz, Eda, Inan, Salim Yalcin, Ayla, Sule, Sahin, Ayse Saide, Oktem, Gulperi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424247/
https://www.ncbi.nlm.nih.gov/pubmed/34512945
http://dx.doi.org/10.1155/2021/5553480
_version_ 1783749636239917056
author Soner, Burak Cem
Acikgoz, Eda
Inan, Salim Yalcin
Ayla, Sule
Sahin, Ayse Saide
Oktem, Gulperi
author_facet Soner, Burak Cem
Acikgoz, Eda
Inan, Salim Yalcin
Ayla, Sule
Sahin, Ayse Saide
Oktem, Gulperi
author_sort Soner, Burak Cem
collection PubMed
description Parkinson's disease (PD) is the second most common neurodegenerative disorder, and the main cause of PD is still not known. Until now, no cure for Parkinson's disease is yet in sight. Caffeic acid phenethyl ester (CAPE) is a polyphenolic component of the propolis, which can be derived from honeybee hive propolis. We aimed to determine the effect of intrastriatal CAPE administration as a neuroprotective agent on 6-hydroxydopamine (6-OHDA)-induced PD model. Adult male Wistar rats weighing 280–320 g were used. The PD model was induced with unilateral intrastriatal 6-OHDA injection. Treatment groups received 20 μmol/5 μL/4 day and 80 μmol/5 μL/4 day CAPE 24 h after 6-OHDA injection. Eight days after 6-OHDA application, behavioral studies (adhesive tape removal test, open-field test, cylinder test, and apomorphine-induced asymmetric rotational behavior) were performed once more to compare the effects of CAPE on behavior tests. Striatal histological verifications, immunohistochemistry, and stereological quantitation were performed. Our results for the first time showed that, besides improving the motor performance, CAPE treatment also prevents 6-OHDA-induced loss of TH-positive neurons. From our results, CAPE may be a promising clinical agent in the treatment of PD.
format Online
Article
Text
id pubmed-8424247
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-84242472021-09-09 Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats Soner, Burak Cem Acikgoz, Eda Inan, Salim Yalcin Ayla, Sule Sahin, Ayse Saide Oktem, Gulperi Parkinsons Dis Research Article Parkinson's disease (PD) is the second most common neurodegenerative disorder, and the main cause of PD is still not known. Until now, no cure for Parkinson's disease is yet in sight. Caffeic acid phenethyl ester (CAPE) is a polyphenolic component of the propolis, which can be derived from honeybee hive propolis. We aimed to determine the effect of intrastriatal CAPE administration as a neuroprotective agent on 6-hydroxydopamine (6-OHDA)-induced PD model. Adult male Wistar rats weighing 280–320 g were used. The PD model was induced with unilateral intrastriatal 6-OHDA injection. Treatment groups received 20 μmol/5 μL/4 day and 80 μmol/5 μL/4 day CAPE 24 h after 6-OHDA injection. Eight days after 6-OHDA application, behavioral studies (adhesive tape removal test, open-field test, cylinder test, and apomorphine-induced asymmetric rotational behavior) were performed once more to compare the effects of CAPE on behavior tests. Striatal histological verifications, immunohistochemistry, and stereological quantitation were performed. Our results for the first time showed that, besides improving the motor performance, CAPE treatment also prevents 6-OHDA-induced loss of TH-positive neurons. From our results, CAPE may be a promising clinical agent in the treatment of PD. Hindawi 2021-08-30 /pmc/articles/PMC8424247/ /pubmed/34512945 http://dx.doi.org/10.1155/2021/5553480 Text en Copyright © 2021 Burak Cem Soner et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Soner, Burak Cem
Acikgoz, Eda
Inan, Salim Yalcin
Ayla, Sule
Sahin, Ayse Saide
Oktem, Gulperi
Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats
title Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats
title_full Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats
title_fullStr Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats
title_full_unstemmed Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats
title_short Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson's Disease in Rats
title_sort neuroprotective effect of intrastriatal caffeic acid phenethyl ester treatment in 6-oh dopamine model of parkinson's disease in rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424247/
https://www.ncbi.nlm.nih.gov/pubmed/34512945
http://dx.doi.org/10.1155/2021/5553480
work_keys_str_mv AT sonerburakcem neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats
AT acikgozeda neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats
AT inansalimyalcin neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats
AT aylasule neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats
AT sahinaysesaide neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats
AT oktemgulperi neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats